Refine by
Analyzer Product Articles & Analysis
90 news found
Introduction The pharmaceutical industry demands absolute precision, reliability, and safety throughout every stage of production. Whether manufacturing life-saving medicines or performing sensitive research, facilities must maintain strict control over environmental conditions. ...
It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s Mastermind® Genomic ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, will unveil new research at the European Society for Medical Oncology (ESMO) 2024. The study, conducted in collaboration with AstraZeneca, leverages advanced AI-driven techniques to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from ...
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today launched the new generation of the SOPHiA DDM™ Platform. The new-gen SOPHiA DDM™ Platform offers a new architecture designed to more efficiently compute large amounts of data at-scale, while elevating customer experience with integrated access to multimodal ...
In addition, CD BioSciences is continually expanding its portfolio to provide scientists with more efficient tools to analyze multiple nervous system tissue samples simultaneously, facilitating in-depth investigations into disease mechanisms, biomarker discovery, and drug development. With a focus on innovation and precision, CD BioSciences has developed state-of-the-art Nervous ...
Statistical and data science analysis can provide insights into customers’ buying behavior to identify their buying patterns and preferences. It can also determine which products customers prefer and which products sell the best so that the sales model can be adjusted to maximize profits. ...
We guarantee the quality of every final product as all of our products are always thoroughly analyzed by advanced technologies. And we will continuously update our products portfolio to get more diversified needs met.” Commented Anna, one of the representative speakers from CD BioGlyco. To view the whole list of lectin ...
In the pharmaceutical industry, ensuring product safety and efficacy is paramount. Therefore, rigorous testing and analysis procedures are employed to ensure that pharmaceutical products meet the required standards. ...
The 87th China International Medical Equipment Fair (CMEF) opened on 14 May at the National Convention and Exhibition Centre (Shanghai). The exhibition is a trendsetter in the global medical device industry and a "top tier" medical event, with brand representatives from more than 20 countries and regions from around the world showcasing sophisticated products spanning the entire industry chain ...
SeqOne Genomics, provider of nextgeneration genomic analysis solutions for personalized medicine, announces the appointment of Hervé Pouzoullic as Chief Commercial Officer (CCO). He will lead the commercial development of the company to accelerate its growth and strengthen its international presence. Hervé has more than 25 years of experience in sales, business development and ...
Liquid chromatography separates mixtures into separate components, while mass spectrometry detects and analyzes the molecular mass of each component with high molecular specificity and detection sensitivity. ...
This Oxford Nanopore-based analysis was compared with traditional short read sequencing approaches in order to establish a benchmark against current standards of care and hence quantify benefits of nanopore sequencing. So far, the program, has analyzed 15 patients demonstrating the potential of the approach and highlighting the following benefits when compared with short-read ...
MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics service company with a renowned reputation for providing reliable sequencing, genotyping, microarray, and bioinformatics services. The product manager is pleased to announce the launch of the Plasmid Identification service, thus helping researchers to efficiently ...
Now as a corporate member, we have the opportunity to further advance our BVA-100® (Blood Volume Analyzer) technology and strengthen our relationship with heart failure leaders to improve adoption of our products and better the lives of heart failure ...
An internationally recognized entrepreneur, Mr. Breukelman is a pioneer in imaging technology, initially as principal and chairman of IMAX Corporation, followed by significant transformative contributions to medical and scientific research companies in information technology and strategic development. Jack Coats, Chief Executive Officer of CardioWise, Inc., announced that Mr. William A. ...
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a study that examined how Differentiation Scoring (DS) derived from key myeloid biomarkers in individual Myelodysplastic Syndrome (MDS) patients using the Cellworks Platform and Computational Biology Model (CBM) can predict response to Hypomethylating Agents (HMA). In ...
The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare’s most critical decisions—what works best, for ...
ByxCures
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a Cellworks biosimulation pilot study, which examined the impact of mismatch repair deficiency (MRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma (GBM). The biosimulation study validated that TMZ does not trigger ...